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Introduction    
 
Nanotechnologies use processes to create novel materials and particles sized between one to 100 
nanometers, although this metrology is not uncontested.
1
 Nanoparticles (NPs) have different physical, 
chemical and biological properties from their equivalent macro counterparts. There is concern that the 
special properties of some nanoscale materials will present unforeseen human and environmental 
health and safety risks.
2
 Nanoparticles can be categorised as natural or engineered/manufactured. 
Naturally occurring NPs include particles in our atmosphere such as salt at the beach. Engineered NPs 
are the newer phenomenon of intentionally/deliberately created manufactured nanomaterials (mNMs). 
This article is concerned with mNMs.  
 
The key issue explored in this paper is whether New Zealand (NZ) occupational health and safety 
(OHS) legislation provides adequate protection for workers who are exposed to NPs.  I evaluate the 
suitability of NZ regulation of NP exposure in the workplace and the current scientific data on 
occupational disease attributed to NPs.  
 
Approximately NZ$6 million of public money per annum is invested in nanotechnology research and 
development.
3
 Nanoparticles are used in a broad range of consumer products (nanoproducts) such as 
cosmetics, sunscreens, food packaging, paints, textiles and herbal remedies.
4
   There are over 1000 
manufacturer-identified nanoproducts currently on the market
 
and new nanoproducts are entering the 
market at a rapid pace.
5
 An estimated US$2.6 trillion worth of manufactured goods are expected to 
incorporate manufactured nanomaterials (mNMs) by 2014.
6
  The increasing numbers of nanoproducts 
are creating occupational exposures, some of which may be harmful to human health. 
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Given the potential market for nanoproducts, the occupational exposures and the growing evidence 
that “certain applications of nanotechnology will present risks unlike any we have encountered 
before”,
7
 it is important to have adequate regulation of NP exposure in the workplace in order to 
prevent or minimise adverse public health ramifications.     
 
Workers involved at any point throughout the lifecycle of nanoproducts (from laboratories to 
manufacturing facilities) are potentially being exposed to NPs. The exact size of the exposed 
workforce in NZ, Australia or the United States (US) is currently unknown, but studies are being 
conducted.
8
 Numerous organisations have highlighted the OHS concerns raised by NPs. For example, 
the European Agency for Safety and Health at Work recently identified NPs among the top ten 
emerging risks from which workers need protection.
9
 The US National Nanotechnology Advisory 
Panel concluded that OHS is the most serious and immediate health and safety concern raised by 
mNMs.
10
  The NZ Council of Trade Unions,
11
 the Australian Council of Trade Unions
12
 and the 
Australian Manufacturing Workers Union
13
 have demanded nano-specific regulation of NP exposure 
and more research into the health risks of NP exposure. Non-government organisations such as the 





FoE has warned that nanotechnology could present “a repeat of the asbestos tragedy”
15
 and, 
specifically that carbon nanotubes (CNTs), a new form of carbon molecule, may be the new 
asbestos.
16
 The Department of Labour‟s annual report on OHS identifies asbestos related cancer as 
one of the most prevalent occupational diseases with the highest toll.
17 
The similarity between some 
NPs and asbestos fibres could, therefore, present a significant potential OHS burden.  
 
Despite these potential risks, NZ regulation of workers‟ exposure to hazardous materials does not 
address the specific risks associated with NP exposure in the workplace. Other jurisdictions such as 
Australia and the United States face similar regulatory challenges. Reviews initiated by governments 
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  and NZ
22
) 
have recommended changes to the existing legislation to ensure that the instruments adequately 
regulate nanoproducts. Likewise, other commentators have reviewed the suitability of the legislative 
status quo and called for amendments.
23
   
 
In contrast to the “do nothing” regulatory and policy approach,
24
 I argue that the inadequacy of the 
current regulatory regimes for safeguarding human health has been demonstrated. Existing regulations 
will “function only as a filter – allowing particles smaller than the relevant pore size to escape through 
the regulatory process”.
25
 This often occurs because some legislative triggers fail to fire when applied 
to workers‟ exposure to NPs.  
 
 




A NP is a particle with all three external dimensions in the nanoscale: 1-100 nanometers. One 
nanometre is one billionth of a metre. Scientists have been working with nanoscale materials for 
centuries but the relatively recent development of special microscopes, capable of displaying tiny 
particles, has improved researchers‟ ability to work with these materials.  
 
Due to their tiny sizes, NPs have a high surface area to volume ratio. There is an increase in the 
percentage of atoms at the surface and, therefore, more sites for bonding or reacting with surrounding 
materials. The considerably larger surface area per unit mass increases their potentials for 
biopersistence (how long it exists in living tissue) and reactivity. All nanoparticles are „nanosized‟ 
(small) but they are not all the same. They can differ in actual size, shape (some are tubes, others 
spheres etc), surface properties (e.g: charge and porosity) and biopersistence. The nano features of 
these particles include not only size, but also other parameters such as shape, surface chemistry, 
composition, solubility and aggregation.  
 
Approximately 44 elements in the periodic table are commercially available in nano form.
26
 
Nanoparticles, because of their size and the effect that size has on their other properties, exhibit 
different properties from their bulk counterparts. In science, a „property‟ describes how a material acts 
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under certain conditions. Examples of properties are: optical (e.g: colour transparency), electrical (e.g: 
conductivity), physical (e.g: hardness, melting point), chemical (e.g: reactivity). For instance, in terms 
of optical properties, bulk gold appears yellow whereas nanosized gold appears red. Also, gold as a 
bulk material is nontoxic, but gold particles below two nanometres have shown unexpectedly high 




Examples of mNMs include fullerenes (C60 or Buckyballs), carbon nanotubes and metal oxides. These 
are examples of first generation nanoproducts.
28
  Subsequent generations of nanoproducts may change 
in response to electric fields, light or in the presence of specific molecules. Subsequent generations of 
mNMs will create further regulatory challenges because the OHS regulations are not designed to deal 
with the novel properties of these new particles, nor are the standard methodologies adequate for 
testing nanotoxicity in the workplace.  
 
Defining Nanotechnology – Legislative Drafting Difficulties   
 
Nanotechnology has been touted as the “next industrial revolution”.
29
  Defining nanotechnology is 
difficult
30 
 but most commentators describe „nanotechnologies‟ as a multidisciplinary and 
heterogeneous field involving molecular engineering. It can have many applications in, for example, 
medicine, food, and electronics.   
 
Definitions are crucial to the operation of legislation as they assist in establishing the subject matter to 
be regulated and the regulatory scope. The heterogeneity of nanotechnology and NPs has presented 
problems for the drafters of legislation. There is no generally accepted definition within the 
international community. No jurisdiction has a definition for nanotechnology or NPs in OHS 
legislation.  
 
The EU is one of the few jurisdictions that include a legislative provision that defines nanomaterials, 
but this does not appear in OHS law. The EU is attempting to regulate particular product areas in 
which mNMs are used; specifically, foods and cosmetics. The EU‟s Regulation on Novel Foods 
proposes a nano-specific provision which states that “novel food should include foods derived from 
plants and animals, produced by non-traditional breeding techniques, and foods modified by new 
production processes, such as nanotechnology and nanoscience, which might have an impact on 
food.”
31
 The EU Cosmetics Directive 2009 defines NM as “an insoluble or biopersistent and 
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In November 2011, the New Zealand Environmental Protection Authority (NZEPA) released its 
Proposals for Amendments to the Cosmetic Products Group Standard (the Standard).
33
 The NZEPA 
may issue group standards under section 96B of the New Zealand Hazardous Substances and New 
Organisms Act 1996 (HSNO). The Standard follows the definition of NM that is used in the EU 
Cosmetics Directive. Proposal 3 proposes introducing a labelling requirement for nanomaterials which 
is in line with Article 19 of the EU Cosmetics Directive (76/768EEC).
34
 These definitions of NM are 
not perfect; for example, they focus on size instead of including other physio-chemical characteristics 
such as shape, charge and surface properties. These provisions represent the first attempt by a 
Parliament to define nanotechnology or mNMs. It is possible that legislative instruments in other 
jurisdictions will be similarly amended to include nano-specific provisions. In my opinion, nano-
specific legislative provisions should be drafted to help protect NZ workers from the risks of exposure 
to NPs.  
  
Characterisation and Measurement of NPs Pose Regulatory Challenges  
 
In addition to the regulatory difficulties in defining NPs, these tiny particles also present other hurdles 
in terms of characterisation and measurement. Effective regulation of NP exposure involves the ability 
to accurately describe and measure the matter being regulated. Under NZ‟s Hazardous Substances and 
New Organisms Act 1996, hazardous substances such as chemicals are conceptualised as „new‟ or 
„existing‟.
35
 How should the nanoscaled version of a chemical be categorised? For example, should 
nanoscaled carbon be distinguished from macroscale carbon? The nanosized version exhibits different 
properties from its macro counterpart; therefore, in my opinion, it should be considered „new‟.   
 
However, the difficulty is that even within one form of nanoscale carbon, there are an array of forms 
and shapes including tubes and spheres. These different surface properties can generate different 
behaviours. To what extent can and/or should any legislative definition include these finer 
distinctions? There is an urgent need for the development of standardised reference NMs. These 
persistent difficulties in the description and definition of NPs will continue to hinder effective 
regulation and risk assessment.  
 
Another regulatory challenge is the difficulties in measuring NPs. The story of asbestos regulation 
also includes difficulties caused by measurement. Inadequate measurement devices should not delay 
the introduction of nano-specific OHS provisions. It is preferable to prevent harm to workers rather 
than to wait for measurement techniques to become available. Also, like asbestos-related disease, 
there may be a long latency (possibly of many decades) before disease symptoms appear.     
   
NPs and Potential Risks to Workers’ Health   
 
Detailed discussions about the health risks and toxicity
36
 of NPs have been undertaken in the 
academic literature. Not all NPs are the same, nor are they all potentially harmful to human and 
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environmental health and safety.  There is growing evidence that the novel properties of some NPs 
will bring unforeseen human and environmental health and safety risks.
37
 The large surface area and 
related increased reactivity of some NPs may mean unpredictable and different reactions with 
biological systems. Generally, the smaller the particles, the more reactive and toxic are their effects.
38
 
The smaller size of NPs means that they can deposit deeper in the respiratory tract than larger 
particles. Nanoparticles may take longer to settle in the air and, therefore, have more chance to travel 
and spread in the workplace, thereby coming into contact with workers.  
 
Carbon nanotubes have been identified as a particularly troubling type of mNM. There are many 
variants of CNTs but they have been broadly categorised as single-walled (consisting of a single layer 
of carbon atoms arranged in a cylinder) and multi-walled (comprising multiple concentric layers of 
single walled tubes with diameters up to tens of nms).
39
 Although further evidence is required, 
preliminary research on CNTs suggests that their structural similarity and low solubility may exhibit 
similar pathology to asbestos.
40
 CNTs are increasingly used in industry because they are 100 times 
stronger than steel but very light. They are, thus, useful in electronics and display devices such as 
LCDs.  The size and fibre shape of CNTs may lead to health effects similar to asbestos.
41
 CNTs can 
cause adverse health effects such as infammation and fibrosis (scarring).
42
 However, the lack of data 
on exposure pathways of certain NPs, combined with uncertainty about the suitability of some 
existing testing methods, is widely recognised as a barrier to the effective implementation of 
regulations.
43
   
 
 
NZ OHS Regulation  
 
The Legislative Framework  
 
NZ workers‟ OHS is regulated by the Health and Safety in Employment Act 1992 (HSE Act), the 
Approved Code of Practice for the Management of Substances Hazardous to Health in the Place of 
Work 1997 (the Code) and the Hazardous Substances and New Organisms Act 1996 (HSNO Act). 
The HSE Act applies to places of work. Duties are imposed on employers (and others) to take all 
practicable steps to ensure healthy and safe workplaces. The concept of „hazard‟ is central to the Act. 
Employers must identify hazards and eliminate, isolate or minimise them. Employers must follow this 
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38 US National Institute of Environmental Health Sciences research presented in a paper by T Hampton “Researchers Size 
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process for hazards, whether or not the hazards involve NPs. The Code applies to all workplaces in 
which hazardous substances are being used or produced, whether or not they contain NPs.  
 
The HSE Act and the Code are administered by the Department of Labour (DoL). Under section 20 of 
the HSE Act, the Minister may approve codes of practice. Compliance with codes is not mandatory 
but they have “powerful persuasive authority”.
44
  One of the DoL‟s roles is to ensure that the HSNO 
Act is complied with in workplaces.  The HSNO Act‟s stated purpose is “to protect the environment, 
and the health and safety of people and communities, by preventing or managing the adverse effects 
of hazardous substances and new organisms”.
45
 The Act applies to everyone who imports, 
manufactures, uses or stores hazardous substances. The HSNO Act‟s provisions relating to hazardous 
substances have the most significance for OHS.  
 
Section 14 of the HSNO Act provides for the establishment of the Environmental Risk Management 
Authority (ERMA). However, following the recent introduction of the Environmental Authority 
Protection Act 2011 (EPA Act), ERMA was disestablished and the Environmental Protection 
Authority (EPA) was established.
46
 The EPA will now administer the HSNO Act.  
 
Regulating ‘Hazard’, ‘Risk’ and ‘Exposure’  
 
Various workplace tasks, such as working with NMs in liquids without adequate protection, will 
increase exposure to NPs. Seven young female Chinese workers developed severe lung damage (and 
two died) after inhaling nanoparticles produced in their factory.
47
 However, the US National Institute 
for Occupational Safety and Health contended that the tragedy could have been avoided by the use of 
proper industrial hygiene procedures.
48
 Debate continues about whether the deaths of the workers can 
be directly linked to their exposure to nanoparticles.    
 
Such incidents have generated increasing debate about the risks to human health posed by NPs and 
how they should be regulated.
49
 In NZ, the regulation of occupational exposures involves quantifying 
and evaluating scientific risk by assessing the relationship between a person‟s exposure and the harm 
caused by that exposure. Risk management involves identifying hazards, assessing exposure and risk, 
and managing those risks.  
 
Hazard identification and characterisation refers to the toxicology of NPs. Although there is limited 
information about the adverse occupational human health effects of NPs, there is cause for concern 
about the health effects of NMs on the basis of three main streams of evidence. First ly, research on 
inhaled dusts and fibres recognises their potential respiratory toxicity.
50
 There is a difference between 
large and nano-sized particles. Air pollution epidemiological studies show that particles less than 2.5 
μm are responsible for respiratory and cardio effects. Research on industrial fibres, such as asbestos 
has established that fibres longer than 15-20 μm with diameters less than 3μm and are biopersistent in 
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45 HSNO Act, s 4.  
46 Environmental Protection Authority Act 2011, s 7.  
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Nanotechnology” Cosmos Online (2011) <www.cosmosmagazine.com>; Reuters “Deaths, Lung Damage Linked to 
Nanotech” (2009) Stuff <www.stuff.co.nz>. 
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49 Royal Commission on Environmental Pollution Novel Materials in the Environment: The Case of Nanotechnology 
(London, RCEP, 2008); Royal Society and Royal Academy of Engineering Nanoscience and Nanotechnologies: 
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the lungs, are hazardous to human health.
51 
Hazard identification and assessment needs to
 
consider the 
role of particle size, chemical properties, shape and dose. Secondly, some familiar materials, when 
nanoscaled, demonstrate heightened biological reactivity.
 
The United States National Institute for 
Occupational Safety and Health (NIOSH) has indicated that low solubility NPs are more toxic than 
larger particles on a mass for mass basis.
52
 Thirdly, initial animal inhalation studies of engineered NPs 
have shown findings of pulmonary fibrosis, granulomas, inflammation, lung cancer, mesothelioma-
like effects and cardiovascular effects.
53
 In these studies, NPs have been shown to translocate from the 




This research provides evidence of the potential occupational hazards of some NPs, but there will only 
be risks to human health if there is exposure at levels in which harm can occur. The most likely route 
of exposure to NPs is through inhalation,
55
 but ingestion and dermal penetration may also occur.
56
 
Detailed discussion of exposure routes has been outlined elsewhere.
57
 There are currently no 
occupational exposure limits governing workplace exposure to NPs. Therefore, NPs present new 
challenges to understanding, predicting and managing potential health risks to workers. It is likely, for 
example, that current personal protective equipment will be of limited effectiveness in reducing 
dermal exposure to NPs because NPs will “more readily be able to penetrate the material from which 




Studies are being conducted to establish the workforce‟s exposure.
59
 It is possible that workers are 
currently experiencing relatively low levels of exposure, but because the toxicity of all NPs is 
unknown, even low exposure could be potentially harmful to human health. Dose metrics besides 
mass concentration may be a better measure when evaluating the health effects of exposure to NPs. 
Currently commercially available air sampling instrumentation can characterise nanoscale aerosols 
based on a number of metrics, but none are sufficiently small to be worn by workers to allow the 
estimation of NP concentration in their personal breathing zone.
60
 Information on exposure remains 




What are the procedures to minimise exposure? At present, there are no standardised or validated 
methodologies or equipment to enable routine measurement of NPs in the workplace.  However, it is 
good public health practice to keep exposures to new and uncharacterised particles as low as possible. 
The NIOSH recently published the results of 12 field studies using the Nanoparticle Emission 
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Assessment Technique to characterise emissions during processes where engineered nanomaterials 
were produced or used.
62
 The NIOSH believes that there is sufficient evidence to suggest that it is 
theoretically possible to control workplace exposure to NPs, but that there will be costs involved.
63
 A 
precautionary approach to the prevention and control of workplace exposures should be adopted.
64
 It 
may be a challenge adopting such an approach because of the way that NZ regulations define and 
address occupational health risks.    
 
Application of Legislative Instruments to Nanoparticles  
 
HSNO Act   
(1) The „substance‟ threshold  
 
Before any particular form of mNM or object containing mNMs will require EPA approval, it must 
satisfy three separate criteria, each of which poses certain challenges with regard to mNMs. The three 
criteria are: 1) is it a „substance‟? 2) is it „hazardous‟? 3) does it present a „new‟ hazard? The HSNO 
Act applies only to “substances” that are “hazardous” and both of those criteria have been subject to 
interpretation and controversy. A “substance” is defined as:
 65
  
a) any element, defined mixture of elements, compounds or defined mixture of compounds, 
either naturally occurring or produced synthetically, or any mixtures thereof; 
b) any isotope, allotrope, isomer, congener, radical, or ion of an element or compound which 
has been declared by the Authority, by notice in the Gazette, to be a different substance 
from that element or compound; 
c) any mixtures or combinations of any of the above; 
d) any manufactured article containing, incorporating, or including any hazardous substance 
with explosive properties. 
 
A substance will be considered hazardous if it meets or exceeds one of the thresholds set down in the 
Hazardous Substances (Minimum Degrees of Hazard) Regulations 2001 for any of the relevant 






iii. a capacity to oxidise; 
iv. corrosiveness; 
v. toxicity (including chronic toxicity); 
vi. ecotoxicity, with or without bioaccumulation.  
 
Where it is possible that a substance may trigger more than one threshold, it should be evaluated 
against the thresholds established for each hazardous property, e.g. a substance that may have both 
flammable and toxic properties must be evaluated against both relevant thresholds.  
 
If a substance does not trigger any of the section 2 thresholds, it is not “hazardous” and does not need 
an approval from the Authority. However, if a substance does trigger a threshold level, then it cannot 
be imported or manufactured in NZ other than in accordance with an approval from the Authority. 
                                                             
62 Methner and others, above n 8.  
63 Ibid.  
64 N Jackson and others “Engineered Nanomaterials: Evidence on the Effectiveness of Workplace Controls to Prevent 
Exposure” (2009) < http://nanotech.law.asu.edu/?rgn=cau>. 
65 HSNO Act, s 2.  
66 HSNO Act, s 2.  
New Zealand Journal of Employment Relations 37(1): 100-117 
 
The manufacture or importation of a hazardous substance without an approval is an offence.
67
 Some 
nano-chemicals will trigger the legislative thresholds and be deemed hazardous.     
 
However, the existence of quantity-based regulatory triggers is a significant regulatory gap. The 
Monash Report reached the same conclusion and its opinion has led the National Industrial Chemicals 
Notification and Assessment Scheme, the Australian industrial chemicals regulator to propose “to 
administratively exclude nanomaterials which are new chemicals from low volume/low concentration 
exemptions, thereby shifting a post-market audit activity to a pre-market assessment (i.e. new 
nanomaterials to be assessed under permit or certificate categories prior to commercialisation).”
68
   
 
The quantity-based exception under the HSNO Act relates to „small-scale use of hazardous substances 
in research and development or teaching‟.
69
 The adequacy of training and practice within laboratory 
environments to ensure safe handling of mNMs is critical. Research conducted by Canterbury 
University in 2009 suggested that complacency in this regard should be avoided.
70
 The report 
identified a number of issues of potential concern, specifically:
71
 
 There is limited information on the effectiveness of engineering controls and personal 
protective clothing to minimise exposure to unbound NPs. 
 Ensuring that researchers have access to best practice safety information for working with 
nanomaterials and that risk or safety assessments are completed. 
 A lack of documented training for new researchers in safe practices for working with 
nanomaterials. 
 Not all nanomaterials research is undertaken in dedicated facilities. A mechanism is needed to 
ensure that other researchers in shared facilities are aware of any hazards and associated 
precautionary measures. 
 The lack of readily available funding for upgrading research facilities to meet health and safety 
requirements.
 
   
 
(2) Is the substance „new‟? 
 
Even if something is agreed to be a “hazardous substance”, an application will only be required if it 
has not already received approval. The question inevitably arises as to whether a nano-form of a 
previously approved substance would be regarded as a new substance, requiring its own approval, or 
alternatively, would be deemed to be covered by the existing approval. The Monash Report referred to 
this as “possibly the most significant potential gap”, pointing out that “uncertainty exists as to whether 
the nanoentity would be considered as „new‟ or „different‟ from or as the same as its‟ [sic] 
conventional counterpart.”
72
 The Australian toxic dust Senate Committee inquiry recommended that 
there be an urgent consideration of whether materials already classified as safe at the macroscale 




Similar uncertainty may be said to apply to applications for nanoforms of substances already present 
in NZ. As ERMA has said:  
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if the hazards of the nanomaterial are the same as the „conventional‟ substance, then they are 
covered by the approval for the „conventional‟ substance.  It is only where the hazards differ 
between the „conventional‟ substance and the nano substance that the nano substance would 




A question inevitably arises as to how a nanoform of an existing substance will be classified where 
there is uncertainty about the hazard profile. Should it be assumed that the hazards are identical until 
data exists to prove otherwise? Or should the default position be that the nano-form may have distinct 
hazardous properties, meriting a separate approval? These issues raise the question of where the 
burden of proof should lie and what standard of proof should be required. These regulatory gaps in 
HSNO may mean that workers exposed to hazardous substances and NPs are not receiving adequate 
protection. These gaps could potentially be addressed by the regulators without need to amend the 
legislation. EPA could, for example, modify its Group Standards
75
 to require that nano-forms of 




The HSE Act enacts an extensive statutory regime to ensure the health and safety of employees and 
other people in the workplace. The Act is less concerned with prescribing how to make workplaces 
safe and more concerned with putting obligations on employers and employees to ensure that 
workplaces and work practices meet defined standards of health and safety. NZ has a „no fault‟ 
scheme for dealing with accidental injury.  
 
The HSE Act‟s object is to promote the prevention of harm to all persons at work as well as others in, 
or in the vicinity of, a place of work.
76
 The Act covers „places of work‟ which is given a broad 
definition in section 2. Therefore, the HSE Act will apply to places of employment whether or not 
those workplaces involve employees working with mNMs or exposed to NPs.  The Act applies to 
employers, employees, self-employed people, contractors and subcontractors
77
 and will, therefore, 
apply to all these people whether or not they work with mNMs.  
 
The Act imposes duties on employers to ensure the safety of employees at work. Most duties under 
the HSE Act are not absolute, but require “all practicable steps”
78
 to have been taken. This phrase 
recurs throughout the Act. The “all practicable steps” requirement is interpreted strictly.
79
 It is 
reasonable to expect an employer to do anything that it is practicable to do.
80
 Employers are expected 
to be proactive in identifying both existing and potential hazards and taking steps to prevent harm to 
workers. Employers may be expected, therefore, to be proactive in identifying potential hazards 
associated with mNMs and NPs.    
 
An assessment of whether or not all reasonable steps have been taken analyses:
 81
  
 the nature and severity of the harm that may be suffered if the result is not achieved; 
 the current state of knowledge about the likelihood that harm of that nature and severity will be 
suffered if the result is not achieved; 
 the current state of knowledge about harm of that nature; 
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 the current state of knowledge about the means available to achieve the result and the likely 
efficacy of those means; and  
 the availability and cost of each of those means available.   
 
A person required by the Act to take all practicable steps is required to take those steps only in respect 
of circumstances that the person knows or ought reasonably to know about.
82
 Therefore, a person is 
required to take all practicable steps to ensure the safety of employees working with NMs or exposed 
to NPs only in respect of circumstances that the person knows or ought reasonably to know about. The 
issue is whether a person required by the Act to take all practicable steps would be aware of the 
presence of NPs and their potential health risks.  
 
There is a potential regulatory gap in that the “current state of knowledge”
83
 regarding harm attributed 
to some mNMs is preliminary. Although initial studies indicate that adverse health consequences are 
possible from some mNMs and NP use and exposure, some of the OHS implications of mNMs and 
NPs are currently unknown.
84
   
 
The HSE Act sets out specific duties on employers in relation to hazards in the workplace. Employers 
must identify hazards;
85
 take all practicable steps to eliminate them;
86
 and if they cannot be 
practicably eliminated, isolate hazards.
87
 If hazards cannot be isolated, they must be minimised.
88
 
Employees exposed to them must be monitored.
89
 The general language of the Act requires a broad 
approach by employers to potential hazards. It is clear that employers must identify specific hazards 
and then do whatever they can to ensure that the hazards do not cause harm. 
 
The concept of „hazard‟ is vital to the working of the Act. Hazard means any activity, arrangement, 
circumstance, event, occurrence, phenomenon, process, situation, or substance that is an actual or 
potential cause or source of harm, whether it arises or is caused within or outside a workplace.
90
 
“Substance” means a thing that is an organic material, whether living or not.
91
 The definition of 
hazard in the HSE Act is broad and may be physical, biological or mental.  
 
“Significant hazard” means a hazard that is an actual or potential cause or source of:
92
 
 serious harm; 
 harm (that is less than trivial) for which the severity of the effect on a person depends on the 
extent or frequency of the person‟s exposure to the hazard; or  
 harm that does not usually occur or that is not easily detectable until a significant time after the 
exposure to the harm.  
 
“Harm” means illness, injury or both and includes physical or mental harm caused by work-related 
stress.
93
 “Serious harm” means death or some other harm declared to be serious harm by the 
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 Any illness, injury, physical or mental harm, or death, whether or not attributable 
to exposure to NPs may be caught by these definitions, provided that the harm caused is deemed 
sufficiently serious. The current gaps in public health knowledge about NP hazards and exposure 
mean that some NPs may not be considered a significant hazard. Also, there may be a prolonged 
latency period between first exposure to NPs and onset of the first symptoms of the disease, 
particularly for CNTs with their asbestos-like pathogenicity. If the deficiencies in nanotoxicology 
prevent a potentially harmful NM from being identified as a significant hazard, this is a significant 
regulatory gap. However, significant hazard is defined in the HSE Act as an actual or potential cause 
or source of serious harm.
95
 If the mNM is deemed a potential cause of harm, it could theoretically be 
identified as a significant hazard and, therefore, trigger the hierarchy of action.  
 
This definition of „hazardous‟ raises the question of standard of proof. How compelling must the 
evidence be before such triggers are activated? Whether carbon nanotubes, for example, should be 
deemed “hazardous substances” within the terms of the HSNO Act seems at present to be uncertain.
96
 
For some commentators with whom I spoke during the review, existing evidence about CNTs is 
sufficient to justify a moratorium on their use, or at least on certain uses to which they could be put 
while for others, the studies published to date are preliminary and inconclusive. 
 
The limited state of current knowledge about the risks posed by some NPs presents a number of 
obstacles to any attempt to regulate in this area. Regulatory triggers requiring “significant hazard” to 
be demonstrated may fail to fire for some NPs. It is obviously important that regulators remain 
apprised of the most recent reliable information with regard to the possible hazards presented by NPs. 
More challenging, however, is the question of how to proceed in situations of uncertainty. With regard 
to burden of proof, should regulators assume that a nanoform of an existing product is safe until 
reliable evidence shows otherwise? Or should they operate on the contrary assumption: that a new 
product is unsafe until the contrary can be demonstrated? 
 
Some regulatory frameworks offer some guidance in this regard. The HSNO Act, for example, adopts 
a “precautionary approach”, which emphasises “the need for caution in managing adverse effects 
where there is scientific and technical uncertainty about those effects”.
97
 However, a range of opinions 
can be found as to how „caution‟ is to be understood. ERMA‟s view is that “while the HSNO Act 
provides for decisions to be precautionary where there is scientific or technical uncertainty … it does 
not empower ERMA to act when there are suspicions but little or no evidence.”
98
 This understanding 
of the precautionary remit is likely to be controversial, not least because it may be thought that many 
of the situations in which there is „scientific or technical uncertainty‟ will arise precisely because 
„there are suspicions but little or no evidence‟.  
 
This is far from a straightforward matter. As one leading commentator on the regulation of emerging 
technologies has said, “there is scope for endless argument about just how strong the evidence needs 
to be before precaution kicks in.”
99
 Insofar as existing OHS regulations are not specific about the level 
of proof that would be required to trigger regulatory action, this is a regulatory gap which may 
compromise workers‟ health. 
 
“Health” and “healthy” have restricted meanings; they simply mean unharmed.
100
 The definition of 
health under the HSE Act is different from the broad World Health Organisation definition of health. 
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Health, according to the WHO, is a state of complete physical, mental and social well-being and not 
merely the absence of disease or infirmity.
101
 The legislative definition of healthy has implications for 
the level of protection available to workers exposed to NPs. Given the uncertainties, risks assessors 
and regulators could address the issue by “considering the lowest toxic dose values, and/or a worst-




The Code 1997   
 
The Code is a statement of preferred work practices and arrangements. The Code is a practical guide 
on how to comply with the applicable sections of the HSE Act and Regulations 1995 in order to 
minimise the risk of occupational illness or injury due to exposure to substances hazardous to 
health.
103
   The Code applies to all workplaces in which substances hazardous to health are used or 
produced and to all persons with potential exposure to substances hazardous to health in those 
workplaces.  
 
The Code does not apply to asbestos and materials containing asbestos because asbestos is covered by 
other regulatory instruments. Given the potential structural and pathogenic similarity between some 
NPs and asbestos, and the potential adverse health effects, it may be prudent to draft a nano-specific 
Code or include nano-specific provisions in the HSE Act, The Code and/or the HSNO Act.  
 
A substance hazardous to health is defined as any substance, or product containing a substance, to be 





   
 Those substances that are classified as hazardous under the HSNO Act, excluding micro-
organisms;  
 Scheduled toxic substances under the HSNO Act; and  
 Those substances that are listed in the Workplace Exposure Standards publication currently 
applicable in New Zealand.  
 
Therefore, many substances that may be or may incorporate NMs such as paints, heavy metals and 
solvents will trigger The Code.   
 
Under The Code there is no provision for formal approval of hazardous substances from DoL prior to 
supply, sale, use or import because such approval is covered by the HSNO Act. In order to achieve 
compliance with sections 6 and 8 to 10 of the HSE Act, The Code provides a hierarchy of prevention 
and control measures. Where a significant hazard has been identified, the HSE Act requires that the 
hazard be managed by considering the following hierarchy of action:  
 Elimination;106 then  
 Isolation;107 and finally  
 Minimisation.108   
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If NPs are identified as a significant hazard, they could be eliminated, isolated or minimised. A 
potential regulatory gap may exist if the deficiencies in nanotoxicology prevent a potentially harmful 
NP from being identified as a significant hazard.  
 
Minimisation of the risk of substances hazardous to health may be achieved by a variety of practices 
such as personal protective equipment (PPE). However, it is likely that NPs will be able to penetrate 
the material from which the protective clothing is made more readily than macro particles.
109
 Another 
regulatory gap is that, under The Code there, is no legal requirement for the supplier of a substance 
hazardous to health to provide specific health and safety information under the requirements for 
labelling and SDS under the HSNO Regulations. The Code states that suppliers should have SDS 




The SDS describes the identity of the substance, relevant health hazard information, precautions for 
use and safe handling, disposal and emergency response information. Identification of the hazardous 
substance requires suppliers to detail the chemical identity and CAS Number of the substance. This 
identification will not necessarily reflect the fact that the chemical is in nanoform. The Code does not 
expressly distinguish between nano and conventional forms of substances.   
 
The physical and chemical properties of the substance are to be included. The supplier could describe 
the particle size of the substance in these sections of the SDS, but the supplier is not required to do so. 
Toxicological information is required but the deficiencies in the toxicological data for NPs, 
particularly for chronic exposure, may preclude inclusion of such information. In addition to SDS, 
The Code states that suppliers should ensure that any container supplied for use in a place of work 
carries sufficient information for the safe use of the product it contains, and is labelled in a way that 
allows for positive identification of the product. The HSNO Act requirements are now applicable. 
Labelling requirements will apply to containers of hazardous substances whether or not they 
incorporate NMs. However, whether users are alerted of the presence of NPs depends on whether the 
product name, number or identifier used on the label references nano and there are currently no 
requirements to do so. 
 
Nano-specific labelling is a contentious topic.
111
 The EU recently legislated for compulsory labelling 
of cosmetics containing mNMs
112
 while a proposal to require nano-specific labelling of novel foods is 
currently the subject of conciliation proceedings involving the EU Parliament, Council and 
Commission.
113
 At present, the only potential nano-specific labelling requirement in NZ is the 
proposed amendment to the NZ Cosmetic Products Group Standard discussed earlier.
114
 This proposal 
has not been approved. This lack of labelling could be argued, in some contexts, to be a regulatory 
gap. In relation to OHS regulation, for example, lack of nano-specific labelling could compromise 
workers‟ health and safety. Due consideration would have to be paid to the appropriate wording of 




Challenges in Safety Assessment for NPs  
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The HSE Act does not specify a particular method of hazard identification. Various hazard 
identification methods are used in industry. Information from manufacturers, designers, safety data 
sheets, product labelling should be reviewed as part of the hazard identification process.  
 
Risk assessment, including hazard identification methods, may not be appropriate for NPs. It may be 
necessary to amend the Safety Data Sheets (SDS) and labelling systems to recognise that NPs have 
different properties from their bulk counterparts. This presents a challenge to effective risk assessment 
of NPs because current regulatory requirements for risk assessment are based on knowledge of 
bulk/conventional particles. The toxicity of NPs is related to properties such as surface area rather 
than weight. Current processes may not consider the high surface area and increased reactivity of NPs. 
The relationship between volume of material and exposure (used in chemicals regulation such as the 
HSNO Act) is not appropriate for assessing the risks of NPs. Therefore, the current methods and 
procedures will be inadequate for the safety of workers. Hazard assessments for NPs need to consider 
shape, chemical properties, functionality, and the role of particle size. 
 
There are further difficulties in protecting New Zealand workers from adverse health effects of 
nanoparticle exposure. Firstly, there is no national or international agreed definition to describe 
nanoparticles. There are, however, attempts to develop an international terminology for 
nanotechnology.
115
 Secondly, equipment and methods to enable routine measurements of 
nanoparticles are not yet available. The tiny size of NPs poses special challenges of exposure. NPs can 
penetrate deep into the lungs when inhaled and may circulate throughout the human body when they 





The HSE Act includes provisions for recording, reporting, reviewing and monitoring hazards in 
workplaces and workers‟ health and safety. For example, Workplace Exposure Standards enable 
monitoring. When sufficient nanotoxicological and exposure data become available, nano-specific 
workplace exposure standards should be developed. The HSE Act confers powers on inspectors who 
may monitor conditions in workplaces.
117
 It is important that these monitoring and reporting 
procedures enable the timely and proper collection of information about exposure to NPs which has 
caused harm, incidents and injuries.   
 
The Code describes an assessment process for employers to meet their duty to manage substances 
hazardous to health. The assessment aims to achieve compliance with section 7 of the HSE Act. The 
purpose of an assessment is to gain adequate information on the use of substances hazardous to health 
in the workplace.
118
 The assessment process involves:  
1. Identifying substances hazardous to health in the workplace;  
2. Reviewing the information about the hazards they pose to health;  
3. Determining the degree of exposure;  
4. Assessing the risk to health; and  
5. Reviewing the assessment.  
 
There are currently no effective methods available in the workplace to measure nanoparticles or 
exposure to nanoparticles, nor are there currently effective methods for assessing particle surface area. 
Therefore, the assessment process described in The Code will be difficult for hazardous substances 
that contain NMs or for nanoparticles.  The Code describes a process if the outcome of an assessment 
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is uncertain. If an assessment indicates that harm to health may result from exposure to substances 
hazardous to health, but there is some uncertainty about the degree and extent of the exposure, then 
further work such as monitoring, workplace exposure monitoring
119
 and biological exposure 
monitoring
120
 is required.  
 
Assessments should be revised at least every two years, or if:
121
 
 The process, plant or substance related to exposure to the substances hazardous to health is 
modified;  
 New information on the hazards of substances becomes available;  
 Monitoring indicates inadequate exposure control… 
 
Hazardous substances containing NPs may trigger a revision if the substance is modified or if new 
information on the substance becomes available. For instance, new epidemiological information on 
human exposure and nanotoxicological data may prompt a revision.   
 
The Code also provides for health surveillance as a measure directed at controlling exposure to 
substances hazardous to health to ensure the health and safety of people at work.
122
 Therefore, 
monitoring is required, but this depends on the assessment showing that monitoring and surveillance 
is required. The current deficiencies in public health knowledge about NPs mean it is unclear whether 
assessments will identify NPs. Further, this limited knowledge means that health surveillance and 
monitoring processes under The Code may not be suitable or adequate for NPs.   
 
 
Suggestions for the Nano-specific Regulation  
 
Given that workers are being exposed, it is important that Parliament acts now. There should be 
compulsory reporting of any incidents of adverse health outcomes experienced by workers exposed to 
NPs. Such a reporting scheme should be national and use standardised identification and hazard 
assessment processes. Any OHS legislation provision which defines NP should refer to size and other 
relevant physio-chemical properties such as shape. The definition should be sufficiently flexible to 
allow for adaptation as nanoscience develops and new public health data on NPs and their health 
effects becomes available.   
 
At the time of writing, neither ERMA nor the EPA had formally assessed the potentially hazardous 
nature of CNTs, as no application involving them has been under the HSNO Act.  There is merit in the 
suggestion that, for the time being, CNTs be classified “as if” they are hazardous, thereby bringing 







Although more work is needed to measure the health and safety risks that NPs pose to NZ employees, 
workers are currently being exposed. This paper has demonstrated that NZ‟s OHS regulation of NPs 
contains the following specific regulatory gaps: 
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 Legislative thresholds such as “significant hazard” and “current state of knowledge” may not 
be triggered because of the current limited public health data on exposure to NPs; 
 NZ OHS regulations are not specific about the level of proof that would be required to trigger 
regulatory action for hazardous substances or particles and this regulatory gap may 
compromise workers‟ health; 
 Despite the risks posed by some NPs, there is not necessarily any requirement for the special 
properties of NPs to be identified in the occupational context; 
 The regulatory deficiencies presented by SDS, labelling and PPE pose health risks to workers 
exposed to NPs; 
 The quantity based thresholds under the HSNO Act are inappropriate for NPs;  
 The uncertainty about whether a nano-form of a substance will be considered „new‟ or 
„existing‟ may mean that workers exposed to hazardous substances and NPs are not receiving 
adequate protection; and  
 There is no NZ regulatory definition of NP, despite the potential need for a definition to ensure 
effective oversight of occupational exposure to NPs.  
 
The deficiencies identified in NZ OHS law are particularly troublesome for NPs because of their 
fundamental differences from standard particles, and due to their unpredictable behaviours when 
interacting with the human body and (in the case of some CNTs) their structural and pathogenic 
similarity to asbestos.    
 
There is current uncertainty in the scientific literature and limited occupational exposure data. 
However, preliminary research does highlight the need to adopt a precautionary approach. NZ‟s 
regulatory risk assessment approach tends to deal retrospectively with well-established occupational 
hazards. We could learn from the regulatory story of asbestos and, without delay, use the steadily 
emerging evidence of the potential asbestos-like pathogenicity of some CNTs to enact OHS law to 
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